{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:49:24Z","timestamp":1791650964779,"version":"4.3.4"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00134-020-06240-x","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:03:07Z","timestamp":1601366587000},"page":"2001-2014","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["Invasive candidiasis in critical care: challenges and future directions"],"prefix":"10.1007","volume":"46","author":[{"given":"C.","family":"Logan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5834-4063","authenticated-orcid":false,"given":"I.","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bicanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"6240_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/cid\/cit006","volume":"56","author":"CJ Clancy","year":"2013","unstructured":"Clancy CJ, Nguyen MH (2013) Finding the missing 50% of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56:1284\u20131292. https:\/\/doi.org\/10.1093\/cid\/cit006","journal-title":"Clin Infect Dis"},{"key":"6240_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-2766-1","author":"J Poissy","year":"2020","unstructured":"Poissy J, Damonti L, Bignon A et al (2020) Risk factors for candidemia: a prospective matched case-control study. Crit Care. https:\/\/doi.org\/10.1186\/s13054-020-2766-1","journal-title":"Crit Care"},{"key":"6240_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/viru.26187","volume":"5","author":"J Delaloye","year":"2014","unstructured":"Delaloye J, Calandra T (2014) Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence 5:161\u2013169. https:\/\/doi.org\/10.4161\/viru.26187","journal-title":"Virulence"},{"key":"6240_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/CCM.0b013e318206c1ca","volume":"39","author":"DH Kett","year":"2011","unstructured":"Kett DH, Azoulay E, Echeverria PM, Vincent JL (2011) Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39:665\u2013670. https:\/\/doi.org\/10.1097\/CCM.0b013e318206c1ca","journal-title":"Crit Care Med"},{"key":"6240_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13054-016-1229-1","volume":"20","author":"JA Paiva","year":"2016","unstructured":"Paiva JA, Pereira JM, Tabah A et al (2016) Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Crit Care 20:53. https:\/\/doi.org\/10.1186\/s13054-016-1229-1","journal-title":"Crit Care"},{"key":"6240_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","volume":"23","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Giacobbe DR, Vena A et al (2019) Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care 23:219. https:\/\/doi.org\/10.1186\/s13054-019-2497-3","journal-title":"Crit Care"},{"key":"6240_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","volume":"25","author":"P Koehler","year":"2019","unstructured":"Koehler P, Stecher M, Cornely OA et al (2019) Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect 25:1200\u20131212. https:\/\/doi.org\/10.1016\/j.cmi.2019.04.024","journal-title":"Clin Microbiol Infect"},{"key":"6240_CR8","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","volume":"41","author":"M Bassetti","year":"2015","unstructured":"Bassetti M, Righi E, Ansaldi F et al (2015) A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 41:1601\u20131610. https:\/\/doi.org\/10.1007\/s00134-015-3866-2","journal-title":"Intensive Care Med"},{"key":"6240_CR9","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMra1315399","volume":"373","author":"BJ Kullberg","year":"2015","unstructured":"Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. N Engl J Med 373:1445\u20131456","journal-title":"N Engl J Med"},{"key":"6240_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1086\/499057","volume":"42","author":"BJ Spellberg","year":"2006","unstructured":"Spellberg BJ, Filler SG, Edwards JE (2006) Current treatment strategies for disseminated Candidiasis. Clin Infect Dis 42:244\u2013251. https:\/\/doi.org\/10.1086\/499057","journal-title":"Clin Infect Dis"},{"key":"6240_CR11","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.1038\/ncomms5675","volume":"5","author":"V Kumar","year":"2014","unstructured":"Kumar V, Cheng S-C, Johnson MD et al (2014) Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. Nat Commun 5:4675. https:\/\/doi.org\/10.1038\/ncomms5675","journal-title":"Nat Commun"},{"key":"6240_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00134-017-5043-2","volume":"44","author":"J-L Vincent","year":"2018","unstructured":"Vincent J-L, Lefrant J-Y, Kotfis K et al (2018) Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP). Intensive Care Med 44:337\u2013344. https:\/\/doi.org\/10.1007\/s00134-017-5043-2","journal-title":"Intensive Care Med"},{"key":"6240_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00134-016-4273-z","volume":"42","author":"C Karagiannidis","year":"2016","unstructured":"Karagiannidis C, Brodie D, Strassmann S et al (2016) Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 42:889\u2013896. https:\/\/doi.org\/10.1007\/s00134-016-4273-z","journal-title":"Intensive Care Med"},{"key":"6240_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.idc.2017.05.007","volume":"31","author":"T Bell","year":"2017","unstructured":"Bell T, O\u2019Grady NP (2017) Prevention of central line-associated bloodstream infections. Infect Dis Clin N Am 31:551\u2013559","journal-title":"Infect Dis Clin N Am"},{"key":"6240_CR15","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"JL Vincent","year":"2020","unstructured":"Vincent JL, Sakr Y, Singer M et al (2020) Prevalence and outcomes of infection among patients in intensive care units in 2017. J Am Med Assoc 323:1478\u20131487. https:\/\/doi.org\/10.1001\/jama.2020.2717","journal-title":"J Am Med Assoc"},{"key":"6240_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1439-0507.2011.02044.x","volume":"55","author":"AM Tortorano","year":"2012","unstructured":"Tortorano AM, Dho G, Prigitano A et al (2012) Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006\u20132008). Mycoses 55:73\u201379. https:\/\/doi.org\/10.1111\/j.1439-0507.2011.02044.x","journal-title":"Mycoses"},{"key":"6240_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s15010-013-0432-0","volume":"41","author":"MT Montagna","year":"2013","unstructured":"Montagna MT, Caggiano G, Lovero G et al (2013) Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA project). Infection 41:645\u2013653","journal-title":"Infection"},{"key":"6240_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jinf.2017.03.011","volume":"75","author":"O Baldesi","year":"2017","unstructured":"Baldesi O, Bailly S, Ruckly S et al (2017) ICU-acquired candidaemia in France: epidemiology and temporal trends, 2004\u20132013\u2014a study from the REA-RAISIN network. J Infect 75:59\u201367. https:\/\/doi.org\/10.1016\/j.jinf.2017.03.011","journal-title":"J Infect"},{"key":"6240_CR19","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkx444","volume":"73","author":"F Lamoth","year":"2018","unstructured":"Lamoth F, Lockhart SR, Berkow EL, Calandra T (2018) Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 73:i4\u2013i13. https:\/\/doi.org\/10.1093\/jac\/dkx444","journal-title":"J Antimicrob Chemother"},{"key":"6240_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00134-014-3603-2","volume":"41","author":"A Chakrabarti","year":"2015","unstructured":"Chakrabarti A, Sood P, Rudramurthy SM et al (2015) Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 41:285\u2013295. https:\/\/doi.org\/10.1007\/s00134-014-3603-2","journal-title":"Intensive Care Med"},{"key":"6240_CR21","doi-asserted-by":"publisher","first-page":"e59373","DOI":"10.1371\/journal.pone.0059373","volume":"8","author":"M Nucci","year":"2013","unstructured":"Nucci M, Queiroz-Telles F, Alvarado-Matute T et al (2013) Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS ONE 8:e59373. https:\/\/doi.org\/10.1371\/journal.pone.0059373","journal-title":"PLoS ONE"},{"key":"6240_CR22","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1128\/JCM.01283-12","volume":"50","author":"SR Lockhart","year":"2012","unstructured":"Lockhart SR, Iqbal N, Cleveland AA et al (2012) Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two US cities from 2008 to 2011. J Clin Microbiol 50:3435\u20133442. https:\/\/doi.org\/10.1128\/JCM.01283-12","journal-title":"J Clin Microbiol"},{"key":"6240_CR23","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","volume":"6","author":"MA Pfaller","year":"2019","unstructured":"Pfaller MA, Diekema DJ, Turnidge JD et al (2019) Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997\u20132016. Open forum Infect Dis 6:S79\u2013S94. https:\/\/doi.org\/10.1093\/ofid\/ofy358","journal-title":"Open forum Infect Dis"},{"key":"6240_CR24","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/cid\/cit136","volume":"56","author":"BD Alexander","year":"2013","unstructured":"Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724\u20131732. https:\/\/doi.org\/10.1093\/cid\/cit136","journal-title":"Clin Infect Dis"},{"key":"6240_CR25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1128\/JCM.06112-11","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Castanheira M, Lockhart SR et al (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199\u20131203. https:\/\/doi.org\/10.1128\/JCM.06112-11","journal-title":"J Clin Microbiol"},{"key":"6240_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv163","author":"S Vallabhaneni","year":"2015","unstructured":"Vallabhaneni S, Cleveland AA, Farley MM et al (2015) Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008\u20132014. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofv163","journal-title":"Open Forum Infect Dis"},{"key":"6240_CR27","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1128\/AAC.03255-14","volume":"58","author":"CD Pham","year":"2014","unstructured":"Pham CD, Iqbal N, Bolden CB et al (2014) Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690\u20134696. https:\/\/doi.org\/10.1128\/AAC.03255-14","journal-title":"Antimicrob Agents Chemother"},{"key":"6240_CR28","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s00134-018-5363-x","volume":"45","author":"A Cortegiani","year":"2019","unstructured":"Cortegiani A, Misseri G, Chowdhary A (2019) What\u2019s new on emerging resistant Candida species. Intensive Care Med 45:512\u2013515","journal-title":"Intensive Care Med"},{"key":"6240_CR29","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.3201\/eid2509.190040","volume":"25","author":"E Van Schalkwyk","year":"2019","unstructured":"Van Schalkwyk E, Mpembe RS, Thomas J et al (2019) Epidemiologic shift in Candidemia driven by Candida auris, South Africa, 2016\u20132017. Emerg Infect Dis 25:1698\u20131707. https:\/\/doi.org\/10.3201\/eid2509.190040","journal-title":"Emerg Infect Dis"},{"key":"6240_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.15585\/mmwr.mm6901a2","volume":"69","author":"B Ostrowsky","year":"2020","unstructured":"Ostrowsky B, Greenko J, Adams E et al (2020) Candida auris isolates resistant to three classes of antifungal medications\u2014New York, 2019. MMWR Morb Mortal Wkly Rep 69:6\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm6901a2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"6240_CR31","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00134-014-3355-z","volume":"40","author":"P Eggimann","year":"2014","unstructured":"Eggimann P, Pittet D (2014) Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive Care Med 40:1429\u20131448. https:\/\/doi.org\/10.1007\/s00134-014-3355-z","journal-title":"Intensive Care Med"},{"key":"6240_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1128\/AAC.01128-10","volume":"55","author":"O Lortholary","year":"2011","unstructured":"Lortholary O, Desnos-Ollivier M, Sitbon K et al (2011) Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. Antimicrob Agents Chemother 55:532\u2013538. https:\/\/doi.org\/10.1128\/AAC.01128-10","journal-title":"Antimicrob Agents Chemother"},{"key":"6240_CR33","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1128\/AAC.01763-15","volume":"60","author":"RH Jensen","year":"2016","unstructured":"Jensen RH, Johansen HK, S\u00f8es LM et al (2016) Posttreatment antifungal resistance among colonizing Candida isolates in candidemia patients: results from a systematic multicenter study. Antimicrob Agents Chemother 60:1500\u20131508. https:\/\/doi.org\/10.1128\/AAC.01763-15","journal-title":"Antimicrob Agents Chemother"},{"key":"6240_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01412-17","author":"KR Healey","year":"2017","unstructured":"Healey KR, Nagasaki Y, Zimmerman M et al (2017) The gastrointestinal tract is a major source of echinocandin drug resistance in a murine model of Candida glabrata colonization and systemic dissemination. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01412-17","journal-title":"Antimicrob Agents Chemother"},{"key":"6240_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02997","author":"DY Thomaz","year":"2018","unstructured":"Thomaz DY, De Almeida JN, Lima GME et al (2018) An azole-resistant Candida parapsilosis outbreak: clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2018.02997","journal-title":"Front Microbiol"},{"key":"6240_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00591-18","author":"B Goemaere","year":"2018","unstructured":"Goemaere B, Lagrou K, Spriet I et al (2018) Clonal spread of Candida glabrata bloodstream isolates and fluconazole resistance affected by prolonged exposure: a 12-year single-center study in Belgium. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00591-18","journal-title":"Antimicrob Agents Chemother"},{"key":"6240_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13756-016-0132-5","volume":"5","author":"S Schelenz","year":"2016","unstructured":"Schelenz S, Hagen F, Rhodes JL et al (2016) First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5:35. https:\/\/doi.org\/10.1186\/s13756-016-0132-5","journal-title":"Antimicrob Resist Infect Control"},{"key":"6240_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fmicb.2018.00726","volume":"9","author":"TSN Ku","year":"2018","unstructured":"Ku TSN, Walraven CJ, Lee SA (2018) Candida auris: disinfectants and implications for infection control. Front Microbiol 9:726","journal-title":"Front Microbiol"},{"key":"6240_CR39","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1056\/NEJMoa1714373","volume":"379","author":"DW Eyre","year":"2018","unstructured":"Eyre DW, Sheppard AE, Madder H et al (2018) A Candida auris outbreak and its control in an intensive care setting. N Engl J Med 379:1322\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1714373","journal-title":"N Engl J Med"},{"key":"6240_CR40","unstructured":"Centers for Disease Control and Prevention (2020) Infection prevention and control for Candida auris. In: Fungal Dis. https:\/\/www.cdc.gov\/fungal\/candida-auris\/c-auris-infection-control.html"},{"key":"6240_CR41","unstructured":"Public Health England (2017) Candida auris: laboratory investigation, management and infection prevention and control. In: Public Health Engl. https:\/\/www.gov.uk\/government\/publications\/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control"},{"key":"6240_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/jof5040111","volume":"5","author":"DH Caceres","year":"2019","unstructured":"Caceres DH, Forsberg K, Welsh RM et al (2019) Candida auris: a review of recommendations for detection and control in healthcare settings. J Fungi 5:111. https:\/\/doi.org\/10.3390\/jof5040111","journal-title":"J Fungi"},{"key":"6240_CR43","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/cid\/cis305","volume":"54","author":"M Kollef","year":"2012","unstructured":"Kollef M, Micek S, Hampton N et al (2012) Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 54:1739\u20131746. https:\/\/doi.org\/10.1093\/cid\/cis305","journal-title":"Clin Infect Dis"},{"key":"6240_CR44","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/CCM.0b013e318236f297","volume":"40","author":"E Azoulay","year":"2012","unstructured":"Azoulay E, Dupont H, Tabah A et al (2012) Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Crit Care Med 40:813\u2013822. https:\/\/doi.org\/10.1097\/CCM.0b013e318236f297","journal-title":"Crit Care Med"},{"key":"6240_CR45","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1097\/00000658-199412000-00008","volume":"220","author":"D Pittet","year":"1994","unstructured":"Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751\u2013758. https:\/\/doi.org\/10.1097\/00000658-199412000-00008","journal-title":"Ann Surg"},{"key":"6240_CR46","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/01.CCM.0000202208.37364.7D","volume":"34","author":"C Le\u00f3n","year":"2006","unstructured":"Le\u00f3n C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (\u201cCandida score\u201d) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730\u2013737. https:\/\/doi.org\/10.1097\/01.CCM.0000202208.37364.7D","journal-title":"Crit Care Med"},{"key":"6240_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1439-0507.2009.01756.x","volume":"54","author":"L Ostrosky-Zeichner","year":"2011","unstructured":"Ostrosky-Zeichner L, Pappas PG, Shoham S et al (2011) Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 54:46\u201351. https:\/\/doi.org\/10.1111\/j.1439-0507.2009.01756.x","journal-title":"Mycoses"},{"key":"6240_CR48","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1513\/AnnalsATS.201811-766OC","volume":"16","author":"Q Haydour","year":"2019","unstructured":"Haydour Q, Hage CA, Carmona EM et al (2019) Diagnosis of fungal infections a systematic review and meta-analysis supporting American thoracic society practice guideline. Ann Am Thorac Soc 16:1179\u20131188","journal-title":"Ann Am Thorac Soc"},{"key":"6240_CR49","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/cid\/ciq206","volume":"52","author":"DE Karageorgopoulos","year":"2011","unstructured":"Karageorgopoulos DE, Vouloumanou EK, Ntziora F et al (2011) d-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52:750\u2013770. https:\/\/doi.org\/10.1093\/cid\/ciq206","journal-title":"Clin Infect Dis"},{"key":"6240_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jmii.2014.06.009","volume":"48","author":"S He","year":"2015","unstructured":"He S, Hang JP, Zhang L et al (2015) A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-\u03b2-d-glucan for invasive fungal infection: focus on cutoff levels. J Microbiol Immunol Infect 48:351\u2013361","journal-title":"J Microbiol Immunol Infect"},{"key":"6240_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/cc9365","author":"M Mikulska","year":"2010","unstructured":"Mikulska M, Calandra T, Sanguinetti M et al (2010) The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European conference on Infections in Leukemia. Crit Care. https:\/\/doi.org\/10.1186\/cc9365","journal-title":"Crit Care"},{"key":"6240_CR52","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.diagmicrobio.2018.10.017","volume":"93","author":"S Wei","year":"2019","unstructured":"Wei S, Wu T, Wu Y et al (2019) Diagnostic accuracy of Candida albicans germ tube antibody for invasive candidiasis: systematic review and meta-analysis. Diagn Microbiol Infect Dis 93:339\u2013345. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.10.017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"6240_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062323","author":"SS Chang","year":"2013","unstructured":"Chang SS, Hsieh WH, Liu TS et al (2013) Multiplex PCR system for rapid detection of pathogens in patients with presumed sepsis\u2014a systemic review and meta-analysis. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0062323","journal-title":"PLoS ONE"},{"key":"6240_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1128\/JCM.01602-10","volume":"49","author":"T Avni","year":"2011","unstructured":"Avni T, Leibovici L, Paul M (2011) PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 49:665\u2013670. https:\/\/doi.org\/10.1128\/JCM.01602-10","journal-title":"J Clin Microbiol"},{"key":"6240_CR55","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1186\/s12879-019-4419-z","volume":"19","author":"DL Tang","year":"2019","unstructured":"Tang DL, Chen X, Zhu CG et al (2019) Pooled analysis of T2 Candida for rapid diagnosis of candidiasis. BMC Infect Dis 19:798. https:\/\/doi.org\/10.1186\/s12879-019-4419-z","journal-title":"BMC Infect Dis"},{"key":"6240_CR56","doi-asserted-by":"publisher","first-page":"e42282","DOI":"10.1371\/journal.pone.0042282","volume":"7","author":"KE Hanson","year":"2012","unstructured":"Hanson KE, Pfeiffer CD, Lease ED et al (2012) \u03b2-d-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS ONE 7:e42282. https:\/\/doi.org\/10.1371\/journal.pone.0042282","journal-title":"PLoS ONE"},{"key":"6240_CR57","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/cid\/ciu074","volume":"58","author":"L Ostrosky-Zeichner","year":"2014","unstructured":"Ostrosky-Zeichner L, Shoham S, Vazquez J et al (2014) MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis 58:1219\u20131226. https:\/\/doi.org\/10.1093\/cid\/ciu074","journal-title":"Clin Infect Dis"},{"key":"6240_CR58","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/cid\/civ707","volume":"61","author":"W Knitsch","year":"2015","unstructured":"Knitsch W, Vincent J-L, Utzolino S et al (2015) A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections. Clin Infect Dis 61:1671\u20131678. https:\/\/doi.org\/10.1093\/cid\/civ707","journal-title":"Clin Infect Dis"},{"key":"6240_CR59","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1001\/jama.2016.14655","volume":"316","author":"JF Timsit","year":"2016","unstructured":"Timsit JF, Azoulay E, Schwebel C et al (2016) Empirical micafungin treatment and survival without invasive fungal infection in adults with ICU-acquired sepsis, candida colonization, and multiple organ failure the empiricus randomized clinical trial. J Am Med Assoc 316:1555\u20131564. https:\/\/doi.org\/10.1001\/jama.2016.14655","journal-title":"J Am Med Assoc"},{"key":"6240_CR60","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/jac\/dkw188","volume":"71","author":"M Nucci","year":"2016","unstructured":"Nucci M, Nou\u00e9r SA, Esteves P et al (2016) Discontinuation of empirical antifungal therapy in ICU patients using 1,3-\u03b2-d-glucan. J Antimicrob Chemother 71:2628\u20132633. https:\/\/doi.org\/10.1093\/jac\/dkw188","journal-title":"J Antimicrob Chemother"},{"key":"6240_CR61","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1007\/s00134-017-4932-8","volume":"43","author":"A Rouz\u00e9","year":"2017","unstructured":"Rouz\u00e9 A, Loridant S, Poissy J et al (2017) Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial. Intensive Care Med 43:1668\u20131677. https:\/\/doi.org\/10.1007\/s00134-017-4932-8","journal-title":"Intensive Care Med"},{"key":"6240_CR62","doi-asserted-by":"publisher","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","volume":"4","author":"PG Pappas","year":"2018","unstructured":"Pappas PG, Lionakis MS, Arendrup MC et al (2018) Invasive candidiasis. Nat Rev Dis Prim 4:18026. https:\/\/doi.org\/10.1038\/nrdp.2018.26","journal-title":"Nat Rev Dis Prim"},{"key":"6240_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/2110-5820-1-37","volume":"1","author":"P Eggimann","year":"2011","unstructured":"Eggimann P, Bille J, Marchetti O (2011) Diagnosis of invasive candidiasis in the ICU. Ann Intensive Care 1:37. https:\/\/doi.org\/10.1186\/2110-5820-1-37","journal-title":"Ann Intensive Care"},{"key":"6240_CR64","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1007\/s00134-002-1540-y","volume":"28","author":"J Garbino","year":"2002","unstructured":"Garbino J, Lew DP, Romand JA et al (2002) Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 28:1708\u20131717. https:\/\/doi.org\/10.1007\/s00134-002-1540-y","journal-title":"Intensive Care Med"},{"key":"6240_CR65","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1097\/01.ccm.0000147726.62304.7f","volume":"32","author":"R Piarroux","year":"2004","unstructured":"Piarroux R, Grenouillet F, Balvay P et al (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32:2443\u20132449. https:\/\/doi.org\/10.1097\/01.ccm.0000147726.62304.7f","journal-title":"Crit Care Med"},{"key":"6240_CR66","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00134-009-1405-8","volume":"35","author":"L Senn","year":"2009","unstructured":"Senn L, Eggimann P, Ksontini R et al (2009) Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 35:903\u2013908. https:\/\/doi.org\/10.1007\/s00134-009-1405-8","journal-title":"Intensive Care Med"},{"key":"6240_CR67","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00134-015-3791-4","volume":"41","author":"D Ferreira","year":"2015","unstructured":"Ferreira D, Grenouillet F, Blasco G et al (2015) Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization. Intensive Care Med 41:1077\u20131088. https:\/\/doi.org\/10.1007\/s00134-015-3791-4","journal-title":"Intensive Care Med"},{"key":"6240_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17030","volume":"17","author":"D Harrison","year":"2013","unstructured":"Harrison D, Muskett H, Harvey S et al (2013) Development and validation of a risk model for identification of non-neutropenic, critically-ill, adult patients at high risk of invasive Candida infection. Health Technol Assess (Rockv) 17:1\u201330. https:\/\/doi.org\/10.3310\/hta17030","journal-title":"Health Technol Assess (Rockv)"},{"key":"6240_CR69","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/jof4010027","volume":"4","author":"CJ Clancy","year":"2018","unstructured":"Clancy CJ, Nguyen MH (2018) Non-culture diagnostics for invasive candidiasis: promise and unintended consequences. J Fungi 4:27","journal-title":"J Fungi"},{"key":"6240_CR70","first-page":"CD004920","volume":"1","author":"A Cortegiani","year":"2016","unstructured":"Cortegiani A, Russotto V, Maggiore A et al (2016) Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 1:CD004920","journal-title":"Cochrane Database Syst Rev"},{"key":"6240_CR71","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00134-015-4053-1","volume":"41","author":"S Bailly","year":"2015","unstructured":"Bailly S, Leroy O, Montravers P et al (2015) Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data. Intensive Care Med 41:1931\u20131940. https:\/\/doi.org\/10.1007\/s00134-015-4053-1","journal-title":"Intensive Care Med"},{"key":"6240_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13613-018-0392-8","volume":"8","author":"K Jaffal","year":"2018","unstructured":"Jaffal K, Poissy J, Rouze A et al (2018) De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety. Ann Intensive Care 8:49. https:\/\/doi.org\/10.1186\/s13613-018-0392-8","journal-title":"Ann Intensive Care"},{"key":"6240_CR73","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.1093\/infdis\/jiaa394","volume":"222","author":"MD Johnson","year":"2020","unstructured":"Johnson MD, Lewis RE, Dodds Ashley ES et al (2020) Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. J Infect Dis 222:S175\u2013S198. https:\/\/doi.org\/10.1093\/infdis\/jiaa394","journal-title":"J Infect Dis"},{"key":"6240_CR74","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00134-019-05599-w","volume":"45","author":"I Martin-Loeches","year":"2019","unstructured":"Martin-Loeches I, Antonelli M, Cuenca-Estrella M et al (2019) ESICM\/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med 45:789\u2013805. https:\/\/doi.org\/10.1007\/s00134-019-05599-w","journal-title":"Intensive Care Med"},{"key":"6240_CR75","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00134-012-2616-y","volume":"38","author":"C Le\u00f3n","year":"2012","unstructured":"Le\u00f3n C, Ruiz-Santana S, Saavedra P et al (2012) Value of \u03b2-d-glucan and Candida albicans germ tube antibody for discriminating between Candida colonization and invasive candidiasis in patients with severe abdominal conditions. Intensive Care Med 38:1315\u20131325. https:\/\/doi.org\/10.1007\/s00134-012-2616-y","journal-title":"Intensive Care Med"},{"key":"6240_CR76","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13054-017-1763-5","volume":"21","author":"DR Giacobbe","year":"2017","unstructured":"Giacobbe DR, Mikulska M, Tumbarello M et al (2017) Combined use of serum (1,3)-\u03b2-d-glucan and procalcitonin for the early differential diagnosis between candidaemia and bacteraemia in intensive care units. Crit Care 21:176. https:\/\/doi.org\/10.1186\/s13054-017-1763-5","journal-title":"Crit Care"},{"key":"6240_CR77","doi-asserted-by":"publisher","first-page":"ofz136","DOI":"10.1093\/ofid\/ofz136","volume":"6","author":"MC Arendrup","year":"2019","unstructured":"Arendrup MC, Andersen JS, Holten MK et al (2019) Diagnostic performance of T2Candida among ICU patients with risk factors for invasive candidiasis. Open forum Infect Dis 6:ofz136. https:\/\/doi.org\/10.1093\/ofid\/ofz136","journal-title":"Open forum Infect Dis"},{"key":"6240_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa075","author":"F Lamoth","year":"2020","unstructured":"Lamoth F, Clancy CJ, Tissot F et al (2020) Performance of the T2Candida panel for the diagnosis of intra-abdominal candidiasis. Open Forum Infect Dis. https:\/\/doi.org\/10.1093\/ofid\/ofaa075","journal-title":"Open Forum Infect Dis"},{"key":"6240_CR79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/21548331.2018.1516105","volume":"46","author":"A Rouze","year":"2018","unstructured":"Rouze A, Poissy J, Sendid B, Nseir S (2018) Biomarkers in early treatment of invasive candidiasis. Hosp Pract 46:239\u2013242. https:\/\/doi.org\/10.1080\/21548331.2018.1516105","journal-title":"Hosp Pract"},{"key":"6240_CR80","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/J.DIAGMICROBIO.2019.04.016","volume":"95","author":"CM Gill","year":"2019","unstructured":"Gill CM, Kenney RM, Hencken L et al (2019) T2 Candida versus beta-d-glucan to facilitate antifungal discontinuation in the intensive care unit. Diagn Microbiol Infect Dis 95:162\u2013165. https:\/\/doi.org\/10.1016\/J.DIAGMICROBIO.2019.04.016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"6240_CR81","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1093\/jac\/dky360","volume":"73","author":"R Rautemaa-Richardson","year":"2018","unstructured":"Rautemaa-Richardson R, Rautemaa V, Al-Wathiqi F et al (2018) Impact of a diagnostics-driven antifungal stewardship programme in a UK tertiary referral teaching hospital. J Antimicrob Chemother 73:3488\u20133495. https:\/\/doi.org\/10.1093\/jac\/dky360","journal-title":"J Antimicrob Chemother"},{"key":"6240_CR82","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01996-19","author":"A Kritikos","year":"2020","unstructured":"Kritikos A, Poissy J, Poissy J et al (2020) Impact of the beta-glucan test on management of intensive care unit patients at risk for invasive candidiasis. J Clin Microbiol. https:\/\/doi.org\/10.1128\/JCM.01996-19","journal-title":"J Clin Microbiol"},{"key":"6240_CR83","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1164\/rccm.201906-1185ST","volume":"200","author":"CA Hage","year":"2019","unstructured":"Hage CA, Carmona EM, Epelbaum O et al (2019) Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice: an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med 200:535\u2013550","journal-title":"Am J Respir Crit Care Med"},{"key":"6240_CR84","doi-asserted-by":"publisher","first-page":"e01756","DOI":"10.1128\/JCM.01756-17","volume":"56","author":"E Mylonakis","year":"2018","unstructured":"Mylonakis E, Zacharioudakis IM, Clancy CJ et al (2018) Efficacy of T2 magnetic resonance assay in monitoring candidemia after initiation of antifungal therapy: the serial therapeutic and antifungal monitoring protocol (STAMP) trial. J Clin Microbiol 56:e01756\u2013e1817. https:\/\/doi.org\/10.1128\/JCM.01756-17","journal-title":"J Clin Microbiol"},{"key":"6240_CR85","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/cid\/cis456","volume":"55","author":"S Jaijakul","year":"2012","unstructured":"Jaijakul S, Vazquez JA, Swanson RN, Ostrosky-Zeichner L (2012) (1,3)-d-Glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis 55:521\u2013526. https:\/\/doi.org\/10.1093\/cid\/cis456","journal-title":"Clin Infect Dis"},{"key":"6240_CR86","doi-asserted-by":"publisher","unstructured":"Angebault C, Lanternier F, Dalle F, et al (2016) Prospective Evaluation of Serum \u03b2-Glucan Testing in Patients With Probable or Proven Fungal Diseases. Open Forum Infect Dis 3:ofw128. https:\/\/doi.org\/10.1093\/ofid\/ofw128","DOI":"10.1093\/ofid\/ofw128"},{"key":"6240_CR87","doi-asserted-by":"publisher","first-page":"E122","DOI":"10.1111\/j.1469-0691.2012.03777.x","volume":"18","author":"S Koo","year":"2012","unstructured":"Koo S, Baden LR, Marty FM (2012) Post-diagnostic kinetics of the (1 \u2192 3)-\u03b2-d-glucan assay in invasive aspergillosis, invasive candidiasis and Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 18:E122\u2013E127. https:\/\/doi.org\/10.1111\/j.1469-0691.2012.03777.x","journal-title":"Clin Microbiol Infect"},{"key":"6240_CR88","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1164\/rccm.201211-2069OC","volume":"188","author":"F Tissot","year":"2013","unstructured":"Tissot F, Lamoth F, Hauser PM et al (2013) \u03b2-Glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 188:1100\u20131109. https:\/\/doi.org\/10.1164\/rccm.201211-2069OC","journal-title":"Am J Respir Crit Care Med"},{"key":"6240_CR89","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1186\/cc13953","volume":"18","author":"J Poissy","year":"2014","unstructured":"Poissy J, Sendid B, Damiens S et al (2014) Presence of Candida cell wall derived polysaccharides in the sera of intensive care unit patients: relation with candidaemia and Candida colonisation. Crit Care 18:R135. https:\/\/doi.org\/10.1186\/cc13953","journal-title":"Crit Care"},{"key":"6240_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1051","author":"DR Giacobbe","year":"2019","unstructured":"Giacobbe DR, Berruti M, Mikulska M (2019) Prognostic impact of negative serum (1,3)-\u03b2-d-glucan in patients with candidemia. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciz1051","journal-title":"Clin Infect Dis"},{"key":"6240_CR91","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/cid\/ciz555","volume":"70","author":"C Agnelli","year":"2020","unstructured":"Agnelli C, Bouza E, Mart\u00ednez-Jim\u00e9nez MDC et al (2020) Clinical relevance and prognostic value of persistently negative (1,3)-\u03b2-d-glucan in adults with candidemia: a 5-year experience in a tertiary hospital. Clin Infect Dis 70:1925\u20131932. https:\/\/doi.org\/10.1093\/cid\/ciz555","journal-title":"Clin Infect Dis"},{"key":"6240_CR92","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/jof6010028","volume":"6","author":"TJ Gintjee","year":"2020","unstructured":"Gintjee TJ, Donnelley MA, Thompson GR (2020) Aspiring antifungals: review of current antifungal pipeline developments. J Fungi 6:28. https:\/\/doi.org\/10.3390\/jof6010028","journal-title":"J Fungi"},{"key":"6240_CR93","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR et al (2015) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62:e1\u2013e50","journal-title":"Clin Infect Dis"},{"key":"6240_CR94","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12039","volume":"18","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Bassetti M, Calandra T et al (2012) ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19\u201337. https:\/\/doi.org\/10.1111\/1469-0691.12039","journal-title":"Clin Microbiol Infect"},{"key":"6240_CR95","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472\u20132482. https:\/\/doi.org\/10.1056\/NEJMoa066906","journal-title":"N Engl J Med"},{"key":"6240_CR96","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1186\/cc10514","volume":"15","author":"DH Kett","year":"2011","unstructured":"Kett DH, Shorr AF, Reboli AC et al (2011) Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 15:R253. https:\/\/doi.org\/10.1186\/cc10514","journal-title":"Crit Care"},{"key":"6240_CR97","doi-asserted-by":"publisher","first-page":"733.e1","DOI":"10.1016\/j.cmi.2016.05.008","volume":"22","author":"LE L\u00f3pez-Cort\u00e9s","year":"2016","unstructured":"L\u00f3pez-Cort\u00e9s LE, Almirante B, Cuenca-Estrella M et al (2016) Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score\u2013derived analysis of a population-based, multicentre prospective cohort. Clin Microbiol Infect 22:733.e1\u2013733.e8. https:\/\/doi.org\/10.1016\/j.cmi.2016.05.008","journal-title":"Clin Microbiol Infect"},{"key":"6240_CR98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10096-015-2527-2","volume":"35","author":"R Murri","year":"2016","unstructured":"Murri R, Scoppettuolo G, Ventura G et al (2016) Initial antifungal strategy does not correlate with mortality in patients with candidemia. Eur J Clin Microbiol Infect Dis 35:187\u2013193. https:\/\/doi.org\/10.1007\/s10096-015-2527-2","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6240_CR99","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","volume":"40","author":"M Bassetti","year":"2014","unstructured":"Bassetti M, Righi E, Ansaldi F et al (2014) A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med 40:839\u2013845. https:\/\/doi.org\/10.1007\/s00134-014-3310-z","journal-title":"Intensive Care Med"},{"key":"6240_CR100","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/CCM.0000000000002867","volume":"46","author":"J Garnacho-Montero","year":"2018","unstructured":"Garnacho-Montero J, D\u00edaz-Mart\u00edn A, Cant\u00f3n-Bulnes L et al (2018) Initial antifungal strategy reduces mortality in critically ill patients with candidemia: a propensity score-adjusted analysis of a multicenter study. Crit Care Med 46:384\u2013393. https:\/\/doi.org\/10.1097\/CCM.0000000000002867","journal-title":"Crit Care Med"},{"key":"6240_CR101","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00134-014-3400-y","volume":"40","author":"AL Colombo","year":"2014","unstructured":"Colombo AL, Guimar\u00e3es T, Sukienik T et al (2014) Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 40:1489\u20131498. https:\/\/doi.org\/10.1007\/s00134-014-3400-y","journal-title":"Intensive Care Med"},{"key":"6240_CR102","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/cid\/ciy827","volume":"68","author":"BJ Kullberg","year":"2019","unstructured":"Kullberg BJ, Viscoli C, Pappas PG et al (2019) Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial. Clin Infect Dis 68:1981\u20131989. https:\/\/doi.org\/10.1093\/cid\/ciy827","journal-title":"Clin Infect Dis"},{"key":"6240_CR103","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/14787210.2018.1528872","volume":"16","author":"S Keane","year":"2018","unstructured":"Keane S, Geoghegan P, Povoa P et al (2018) Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis. Expert Rev Anti Infect Ther 16:839\u2013847","journal-title":"Expert Rev Anti Infect Ther"},{"key":"6240_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-97","author":"J Vazquez","year":"2014","unstructured":"Vazquez J, Reboli AC, Pappas PG et al (2014) Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis. https:\/\/doi.org\/10.1186\/1471-2334-14-97","journal-title":"BMC Infect Dis"},{"key":"6240_CR105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00134-019-05866-w","volume":"46","author":"A Tabah","year":"2020","unstructured":"Tabah A, Bassetti M, Kollef MH et al (2020) Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med 46:245\u2013265. https:\/\/doi.org\/10.1007\/s00134-019-05866-w","journal-title":"Intensive Care Med"},{"key":"6240_CR106","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1007\/s12325-019-01115-0","volume":"36","author":"J Chatelon","year":"2019","unstructured":"Chatelon J, Cortegiani A, Hammad E et al (2019) Choosing the right antifungal agent in ICU patients. Adv Ther 36:3308\u20133320","journal-title":"Adv Ther"},{"key":"6240_CR107","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:737\u2013779","journal-title":"Infection"},{"key":"6240_CR108","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/cc13803","volume":"18","author":"FJ Gonz\u00e1lez de Molina","year":"2014","unstructured":"Gonz\u00e1lez de Molina FJ, de Mart\u00ednez-Alberici MLA, Ferrer R (2014) Treatment with echinocandins during continuous renal replacement therapy. Crit Care 18:218","journal-title":"Crit Care"},{"key":"6240_CR109","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14787210.2016.1199272","volume":"14","author":"FP Tverdek","year":"2016","unstructured":"Tverdek FP, Kofteridis D, Kontoyiannis DP (2016) Antifungal agents and liver toxicity: a complex interaction. Expert Rev Anti Infect Ther 14:765\u2013776","journal-title":"Expert Rev Anti Infect Ther"},{"key":"6240_CR110","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/jac\/dkt542","volume":"69","author":"G Aguilar","year":"2014","unstructured":"Aguilar G, Azanza JR, Carbonell JA et al (2014) Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. J Antimicrob Chemother 69:1620\u20131623. https:\/\/doi.org\/10.1093\/jac\/dkt542","journal-title":"J Antimicrob Chemother"},{"key":"6240_CR111","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1016\/j.clinthera.2016.07.169","volume":"38","author":"J Sherwin","year":"2016","unstructured":"Sherwin J, Heath T, Watt K (2016) Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature. Clin Ther 38:1976\u20131994","journal-title":"Clin Ther"},{"key":"6240_CR112","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1051\/ject\/201749150","volume":"49","author":"KM Watt","year":"2017","unstructured":"Watt KM, Cohen-Wolkowiez M, Williams DC et al (2017) Antifungal extraction by the extracorporeal membrane oxygenation circuit. J Extra Corpor Technol 49:150\u2013159","journal-title":"J Extra Corpor Technol"},{"key":"6240_CR113","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00134-008-1269-3","volume":"35","author":"S Ruiz","year":"2009","unstructured":"Ruiz S, Papy E, Da Silva D et al (2009) Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 35:183\u2013184","journal-title":"Intensive Care Med"},{"key":"6240_CR114","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/jac\/dkp026","volume":"63","author":"I Spriet","year":"2009","unstructured":"Spriet I, Annaert P, Meersseman P et al (2009) Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 63:767\u2013770. https:\/\/doi.org\/10.1093\/jac\/dkp026","journal-title":"J Antimicrob Chemother"},{"key":"6240_CR115","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.medmal.2018.10.011","volume":"49","author":"JB Foulquier","year":"2019","unstructured":"Foulquier JB, Berneau P, Fr\u00e9rou A et al (2019) Liposomal amphotericin B pharmacokinetics in a patient treated with extracorporeal membrane oxygenation. Med Mal Infect 49:69\u201371. https:\/\/doi.org\/10.1016\/j.medmal.2018.10.011","journal-title":"Med Mal Infect"},{"key":"6240_CR116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/phar.2348","volume":"40","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Seelhammer TG, Barreto EF, Wilson JW (2020) Altered pharmacokinetics and dosing of liposomal amphotericin B and isavuconazole during extracorporeal membrane oxygenation. Pharmacotherapy 40:89\u201395. https:\/\/doi.org\/10.1002\/phar.2348","journal-title":"Pharmacotherapy"},{"key":"6240_CR117","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1128\/AAC.00102-15","volume":"59","author":"KM Watt","year":"2015","unstructured":"Watt KM, Gonzalez D, Benjamin DK et al (2015) Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother 59:3935\u20133943. https:\/\/doi.org\/10.1128\/AAC.00102-15","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-020-06240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-020-06240-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-020-06240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T12:19:07Z","timestamp":1696767547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-020-06240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":117,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["6240"],"URL":"https:\/\/doi.org\/10.1007\/s00134-020-06240-x","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"IML has received speaking and advisory board fees from Merck and Gilead Sciences. TB has received speaking fees from Pfizer and speaking, advisory board fees and research support from Gilead Sciences. CL has received research support from Gilead Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}